AIM ImmunoTech Inc. — Director's Dealing 2017

Jul 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-06-30

Reporting Person: Appelrouth Stewart (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-30	Options to buy Common Stock	$0.49	A	17290	Acquired	2027-06-30	Common Stock (17290)	Direct

Footnotes

F1: This option is being issued in exchange for a voluntary 100% reduction in Director's fees.